Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 1,945 Cr.
- Current Price ₹ 540
- High / Low ₹ 607 / 286
- Stock P/E
- Book Value ₹ 407
- Dividend Yield 0.00 %
- ROCE 1.80 %
- ROE -1.44 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 30.5%
- Company has a low return on equity of 3.27% over last 3 years.
- Promoters have pledged 48.0% of their holding.
- Promoter holding has decreased over last 3 years: -13.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,407 | |
464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,463 | |
Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -56 |
OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -4% |
2 | 12 | 27 | 29 | 16 | 22 | -60 | |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 96 |
Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 105 |
Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -317 |
Tax % | -70% | 1% | 0% | 0% | 36% | 50% | |
0 | 59 | 115 | 221 | -58 | -22 | -308 | |
EPS in Rs | 23.09 | 42.68 | 61.62 | -16.15 | -6.16 | -85.64 | |
Dividend Payout % | 0% | 22% | 5% | 11% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 3% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -949% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | -30% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 3% |
Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 |
Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 1,427 |
633 | 538 | 722 | 621 | 1,037 | 1,013 | 985 | |
425 | 466 | 346 | 404 | 383 | 386 | 427 | |
Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,875 |
1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,313 | |
CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 250 |
Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 |
663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 1,310 | |
Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,875 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
49 | 166 | 242 | 155 | -242 | 156 | |
-85 | -113 | -359 | -106 | -243 | -81 | |
68 | -23 | 97 | 92 | 334 | -113 | |
Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 |
Days Payable | 420 | 127 | 132 | 156 | 154 | 142 |
Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 |
Working Capital Days | 107 | 34 | 67 | 118 | 251 | 213 |
ROCE % | 10% | 12% | 15% | -0% | 2% |
Documents
Announcements
- Board Meeting Intimation for Meeting Of The Rights Issue Committee To Be Held On May 9, 2024 7h
- Certificate From A Practicing Company Secretary Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 26 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 26 Apr
- Update On Transfer Of 100% Shareholding In Wholly Owned Subsidiary Company 25 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 24 Apr
Annual reports
Concalls
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Business Segments
It is a global, R&D-focused, pure-play Active Pharmaceutical Ingredients (API) company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. [1]